Company news

Clarity Pharmaceuticals Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Quarterly Activities/Appendix 4C Cash Flow Report

October 30, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

October 30, 2026

Ph III CLARIFY trial target number of participants achieved

October 26, 2026

SECuRE update

October 7, 2026

Bioshares Biotech Summit Presentation

August 5, 2026

Clarity Pharmaceuticals Announces SECuRE Trial Update on 8 GBq 67Cu-SAR-bisPSMA dose level with two additional complete responses

August 5, 2026

SECuRE update

August 4, 2026

Data on SAR-bisPSMA to be presented at EANM

June 28, 2026

Clarity receives $9.8 million R&D tax incentive refund

May 14, 2026

Clarity signs a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with Nucleus RadioPharma

April 14, 2026

Clarity signs a Commercial Manufacturing Agreement

April 13, 2026

Co-PSMA data published in the European Urology journal

March 31, 2026

Clarity signs a large-scale Manufacturing Supply Agreement for copper-64 with Theragenics

March 25, 2026

Clarity signs a large-scale Manufacturing Supply Agreement

March 24, 2026

Co-PSMA data presented at EAU Annual Congress 2026 with manuscript accepted for publication in the European Urology journal

March 17, 2026

Co-PSMA data presented

March 16, 2026

Registrational Phase III AMPLIFY trial: Target number of participants achieved

March 10, 2026

AMPLIFY trial - Target number of participants achieved

March 9, 2026

Half Yearly Report and Accounts

February 26, 2026

SECuRE trial update: Another participant with undetectable PSA & negative PSMA PET

February 23, 2026

SECuRE trial update

February 22, 2026

Co-PSMA: Cu-64 SAR-bisPSMA more than doubled prostate cancer lesion and patient detection vs. Ga-68 PSMA-11 in head-to-head trial

February 16, 2026

Co-PSMA abstract released

February 15, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

January 30, 2026

SECuRE trial to continue with no modifications to protocol following Safety Review Committee meeting

January 15, 2026

SECuRE trial to continue with no modifications to protocol

January 14, 2026

Co-PSMA abstract accepted for oral presentation at EAU Annual Congress 2026

December 24, 2025

Co-PSMA abstract accepted for oral presentation at EAU

December 23, 2025

Positive guidance from the US FDA on Cu-64 SARTATE Phase III

December 21, 2025

AGM MD Presentation

November 24, 2025

Clarity signs copper-67 Supply Agreement with Nusano

October 16, 2025

Co-PSMA trial achieves primary endpoint

October 14, 2025

S&P DJI Announces September 2025 Quarterly Rebalance

September 5, 2025

Preliminary Final Report

August 28, 2025

Clarity successfully completes $203 million institutional pl

July 28, 2025

Co-PSMA trial: Recruitment successfully completed

July 17, 2025

Co-PSMA trial recruitment successfully completed

July 17, 2025

Clarity enters a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with SpectronRx

June 17, 2025

Clarity enters a Commercial Manufacturing Agreement

June 16, 2025

SABRE topline results: Cu-64 SAR-Bombesin is effective in detecting prostate cancer recurrence in patients with negative SOC imaging

June 13, 2025

SABRE topline results

June 13, 2025

DISCO topline results: 64Cu-SARTATE is highly effective in detecting tumours in NET patients compared to SOC imaging. Phase III planning underway.

June 5, 2025

DISCO topline results

June 5, 2025

First patient imaged in Phase III AMPLIFY trial with 64Cu-SAR-bisPSMA PET/CT

May 29, 2025

First patient imaged in Phase III AMPLIFY trial

May 28, 2025

Registrational Phase III AMPLIFY trial in biochemical recurrence of prostate cancer commences

May 20, 2025

AMPLIFY trial commences

May 20, 2025

Clarity signs high-volume commercial-scale copper-64 Supply Agreement with Nusano

April 17, 2025

Clarity signs commercial-scale copper-64 Supply Agreement

April 17, 2025

$11.1 million RDTI and refocus on high-priority programs

April 17, 2025

Older news releases →

Decks

The 5 newest of 22 decks. Every deck is listed under its year.